


European Journal of Clinical Investigation

56TH ANNUAL SCIENTIFIC MEETING –
8–10 June 2022, Bari, Italy



Cholangiocarcinoma - 9 faces of the killer

It shows cholangiocarcinoma, an aggressive bile duct tumour with dismal prognosis,

It was captured during magnetic resonance cholangiopancreatography (MRCP)

Piotr Milkiewicz, Warsaw Poland

European Journal of Clinical Investigation

THE JOURNAL OF THE EUROPEAN SOCIETY FOR CLINICAL INVESTIGATION

EDITOR-IN-CHIEF	Hendrik M. Nathoe	EDITORIAL ADDRESS Bolognalaan 34 3584 CJ Utrecht, The Netherlands Email: EJCloffice@esci.eu.com
DEPUTY EDITOR-IN-CHIEF	Fabrizio Montecucco	
MANAGING EDITORS	Ingrid Meijer. Utrecht, The Netherlands Debbie Barneveld Binkhuijsen. Utrecht, The Netherlands	
PUBLISHER'S OFFICE	Production Editor: Arthi Riya eci@wiley.com	

Aims & Scope

The European Journal of Clinical Investigation (EJCI), in publication since 1970, is a peer-reviewed general-interest biomedical journal with a broad readership. It is the official journal of the European Society for Clinical Investigation (ESCI) and it is published monthly by Wiley. It considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.

Copyright and Copying

Copyright © 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. All rights reserved. No part of this

publication (apart from articles marked 'OnlineOpen') may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (<http://www.copyright.com>), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising and promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissionsuk@wiley.com.

Disclaimer

The Publisher, European Society for Clinical Investigation and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, European Society for Clinical Investigation and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, European Society for Clinical Investigation and Editors of the products advertised.

ISSN 0014-2972 (Print)

ISSN 1365-2362 (Online)

European Journal of Clinical Investigation

THE JOURNAL OF THE EUROPEAN SOCIETY FOR CLINICAL INVESTIGATION

EDITORIAL BOARD

Editor-in-Chief

Hendrik Nathoe Utrecht, The Netherlands

Deputy Editor-in-Chief

Fabrizio Montecucco Genoa, Italy

Managing Editors

Ingrid Meijer Utrecht, The Netherlands

Debbie Barneveld Binkhuijsen Utrecht, The Netherlands

Deputy Editors

Federico Carbone Genoa, Italy

Yvonne Döring Bern, Switzerland

Baris Gencer Boston, USA

Luca Liberale Zurich, Switzerland

Vilma Sardão Coimbra, Portugal

Section Editors

Johann Auer Braunau, Austria

Leonilde Bonfrate Bari, Italy

Marco Canepa Genoa, Italy

Agostino Di Ciauli Bari, Italy

Leo Koenderman Utrecht, The Netherlands

Igor Koncar Belgrade, Serbia

Marcin Krawczyk Warsaw, Poland

Matteo Lambertini Genoa, Italy

Paulo Oliveira Coimbra, Portugal

Piero Portincasa Bari, Italy

Voahanginirina Randriamboavonjy Frankfurt, Germany

Ruslan Rust Zurich, Switzerland

Thomas Schindler St Louis, USA

Angela Angela Sciacqua Catanzaro, Italy

Vanessa Smith Ghent, Belgium

Markus Sperandio Munich, Germany

Mario Strazzabosco New Haven, USA

Marcel Twickler Antwerp, Belgium

Gemma Vilahur Barcelona, Spain

José Viña Valencia, Spain

Hiroshi Yoshida Chiba, Japan

Carmine Zoccali Reggio Calabria, Italy

European Society for Clinical Investigation



Founded 12 February 1967

Officers and members of the ESCI Council 2020

PRESIDENT

Paulo Oliveira, Coimbra, Portugal

PAST PRESIDENT

Hendrik Nathoe, Utrecht, The Netherlands

VICE-PRESIDENT

Voahangy Randriamboavongy, Frankfurt, Germany

SECRETARY-TREASURER

Jakub Regieli, The Netherlands

COUNCILLORS

Federico Carbone, Genoa, Italy

Marcin Krawczyk, Homburg, Germany

Nahid Tabibzadeh, Paris, France

Gemma Vilahur, Barcelona, Spain

ESCI CENTRAL OFFICE

Marliese Greven

Debbie Barneveld Binkhuijsen

Utrecht, The Netherlands

esci@umcutrecht.nl

Objectives

The objectives of the Society are the advancement of medical practice through science; the cultivation of clinical research by the methods of the natural sciences; the correlation of science with the art of medical practice; the fostering of high standards of ethical practice and investigation; and the diffusion of a spirit of fraternity and international co-operation among and through its members.

Membership

Any person who has been actively involved in medical research in Europe, for example by involvement in original investigations in clinical or allied sciences of medicine, can apply for membership of ESCI. Members will receive the *EJCI* monthly. Any company, corporation, organisation, or trust can apply for corporate membership in the Society.

Meetings

The Society holds one Annual Scientific Meeting each year, usually in April/May. Meetings are held in different cities in Europe. Other Society's activities include the sponsorship of Workshops and Postgraduate Courses and the encouragement of the exchange of Scientists between Laboratories.

Contact information ESCI

Enquiries regarding membership of the Society or any of its activities should be addressed to: European Society for Clinical Investigation (ESCI), Central Office, Bolognalaan 34, 3584 CJ Utrecht, Netherlands.

Tel: +31 88 755 8787

esci@umcutrecht.nl;

www.esci.eu.com

European Journal of Clinical Investigation

Volume 52

Supplement 1

June 2022

**56TH ANNUAL SCIENTIFIC MEETING –
8–10 June 2022, Bari, Italy**

These abstracts have been published as they were received via online electronic submission. Every effort has been made to reproduce faithfully the abstracts as submitted. However, no responsibility is assumed by the organizers for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of methods, products, instructions or ideas contained in the materials herein. Because of the rapid advances in medical sciences, we recommend that independent verification of diagnoses and drug doses should be made.

Contents

	<i>Page number</i>
ABSTRACTS	
S1 The Gut-Liver Body Axis & Lifestyles: Lessons from Frontline Biomedical Research	8
S2 Mitochondria	34
S3 Cardiovascular & Metabolic Diseases	62
S4 Bioinformatics and Computational Biology for Biomedicine	88
S5 Clinical Ultrasonography: Tips & Tricks	103
S6 Membrane Channels and Transporters: Translating Basic Research to New Drug Discovery and Preclinical Development	106
S7 Regenerative - Genomic Medicines	124
S8 Multidisciplinary - Collaborative Clinical Investigation Between Medicine & Surgery	139
S9 Transitional, Translational Aspects and Genetics of FMF	159
S10 Microbiome, Metabolome and Lifestyles: More to Know	163
S11 Focus on Gender Medicine	171

European Journal of Clinical Investigation

THE JOURNAL OF THE EUROPEAN SOCIETY FOR CLINICAL INVESTIGATION

EDITORIAL BOARD

Editor-in-Chief

Hendrik Nathoe Utrecht, The Netherlands

Deputy Editor-in-Chief

Fabrizio Montecucco Genoa, Italy

Managing Editors

Ingrid Meijer Utrecht, The Netherlands

Debbie Barneveld Binkhuijsen Utrecht, The Netherlands

Deputy Editors

Federico Carbone Genoa, Italy

Yvonne Döring Bern, Switzerland

Baris Gencer Boston, USA

Luca Liberale Zurich, Switzerland

Vilma Sardão Coimbra, Portugal

Section Editors

Johann Auer Braunau, Austria

Leonilde Bonfrate Bari, Italy

Marco Canepa Genoa, Italy

Agostino Di Ciauli Bari, Italy

Leo Koenderman Utrecht, The Netherlands

Igor Koncar Belgrade, Serbia

Marcin Krawczyk Warsaw, Poland

Matteo Lambertini Genoa, Italy

Paulo Oliveira Coimbra, Portugal

Piero Portincasa Bari, Italy

Voahanginirina Randriamboavonjy Frankfurt, Germany

Ruslan Rust Zurich, Switzerland

Thomas Schindler St Louis, USA

Angela Angela Sciacqua Catanzaro, Italy

Vanessa Smith Ghent, Belgium

Markus Sperandio Munich, Germany

Mario Strazzabosco New Haven, USA

Marcel Twickler Antwerp, Belgium

Gemma Vilahur Barcelona, Spain

José Viña Valencia, Spain

Hiroshi Yoshida Chiba, Japan

Carmine Zoccali Reggio Calabria, Italy

effect of myocardial infarction on the contractility of the isolated rat heart at different stages of MI.

Materials and Methods: The experiments were performed ex vivo on isolated hearts of intact and rats with a model of MI after 1 day, 54 days and 120 days after the simulation. MI was performed according to the classical technique - ligation of the anterior branch of the left coronary artery. The contractile activity was studied on the Langendorff System. The data were statistically processed using Student's t-test.

Results: A comparative analysis of the effect of MI on the initial values of contraction force in the studied groups revealed that in rats the contraction force decreased one day after MI and tended to increase 54 and 120 days after the simulation of MI.

Conclusions: Thus, it was shown that at different stages of the postinfarction period, multidirectional changes of the isolated rat heart myocardium contractions force are observed. The study was supported by Russian Science Foundation (grant No. 21-15-00121, <https://rscf.ru/project/21-15-00121/>)

56ASM-0102 | Effect of HCN channel blocker in the regulation of chronotropic effects in rats with limited motor activity

M. Sungatullina; R. Zaripova; R. Shakirov;
N. Ziyatdinova; T. Zefirov
Kazan Federal University, Department of Human Health Protection, Kazan, Russia C.I.S.

Background: In the modern world, limitation of motor activity is an acute problem, because there are many reasons leading to this way of life. Hypokinesia causes atrophy of the musculoskeletal system, complicates the digestive, respiratory and cardiovascular systems. The involvement of HCN channels in the mechanism of heart rhythm acceleration has been shown. It is interesting to see the effect of blockade of If-currents and their role in the regulation of chronotropy of the heart against the background of increased heart rate (HR) in response to hypokinesia.

Materials and Methods: The experiments were conducted on two groups of rats: 1- control group, rats 7 weeks old; 2 - experimental group, rats with restriction of motor activity for 30 days. This effect was achieved by placing 3-week-old rats in penal cages under conditions of increasing hypokinesia. The effect of If blocker ZD7288 (10^{-9} M and 10^{-6} M) on chronotropic effects was studied using Langendorff PowerLab8/35 (ADInstruments, Australia).

Results: After the introduction into the perfused solution ZD7288 (10^{-9} M), a decrease in heart rate by 15% was observed in control rats ($p < 0.01$) and by 11% ($p < 0.05$) in the experimental group. The blocker If in concentrations 10^{-6} M decreased heart rate in the control group by 28% ($p < 0.01$) and by 17% in experimental group.

Conclusions: If-current blocker ZD7288 at all concentrations caused a decrease in heart rate in control rats and rats, with limitation of motor activity. However, more pronounced changes in heart rate were observed in the control group of rats and after application of the maximum concentration. It is possible that in rats with limited motor activity, against the background of an increase in heart rate, the density of HCN channels decreases compensatory, which leads to decrease their role in the regulation of heart rate. This paper has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030)

56ASM-0103 | Isolated rat heart after restriction of motor activity and recovery

M. Sungatullina; R. Zaripova; L. Mosolov;
N. Ziyatdinova; T. Zefirov
Kazan Federal University, Department of Human Health Protection, Kazan, Russia C.I.S.

Background: Restriction of motor activity becomes a medical and social problem. Restriction of muscle activity leads to violations of all organ systems of the human body. Namely, in the cardiovascular system, prolonged restriction of motor activity leads to coronary vessels, the heart muscle weakening, decreasing of the heart energy potential and minute volume. The aim of our study was to study possible age-related changes in the parameters of the isolated rat heart after hypokinesia and subsequent recovery.

Materials and Methods: Restriction of motor activity was carried out by placing animals in pencil cases in conditions of increasing hypokinesia for 30 days. The recovery stage after hypokinesia for 14 days was carried out in order to study the mechanisms of adaptation of the animal to changes in the motor regime. The following parameters of the isolated heart were recorded - the pressure developed in the left ventricle (LVL), heart rate (HR) and coronary flow (CP) on the Langendorff PowerLab 8/35 unit (ADInstruments, Australia). Statistical processing was carried out in Excel, the reliability was determined using the Student's t-test.

Results: After hypokinesia, unidirectional changes in the parameters of the isolated heart were observed in 7-week-old and adult rats: a decrease in the parameters of the LVL, CP and an increase in heart rate. However,